BIO-FD&CLtd Past Earnings Performance
Past criteria checks 4/6
BIO-FD&CLtd has been growing earnings at an average annual rate of 19%, while the Biotechs industry saw earnings growing at 18.2% annually. Revenues have been growing at an average rate of 10.4% per year. BIO-FD&CLtd's return on equity is 10.3%, and it has net margins of 37.6%.
Key information
18.95%
Earnings growth rate
16.56%
EPS growth rate
| Biotechs Industry Growth | 11.70% |
| Revenue growth rate | 10.36% |
| Return on equity | 10.35% |
| Net Margin | 37.64% |
| Last Earnings Update | 30 Sep 2025 |
Recent past performance updates
BIO-FD&CLtd's (KOSDAQ:251120) Soft Earnings Are Actually Better Than They Appear
May 23
We Think That There Are Some Issues For BIO-FD&CLtd (KOSDAQ:251120) Beyond Its Promising Earnings
Nov 19Recent updates
There's Reason For Concern Over BIO-FD&C Co.,Ltd.'s (KOSDAQ:251120) Massive 30% Price Jump
Jun 18BIO-FD&CLtd's (KOSDAQ:251120) Soft Earnings Are Actually Better Than They Appear
May 23With EPS Growth And More, BIO-FD&CLtd (KOSDAQ:251120) Makes An Interesting Case
Dec 16We Think That There Are Some Issues For BIO-FD&CLtd (KOSDAQ:251120) Beyond Its Promising Earnings
Nov 19Some Shareholders Feeling Restless Over BIO-FD&C Co.,Ltd.'s (KOSDAQ:251120) P/E Ratio
Oct 14A Look At The Fair Value Of BIO-FD&C Co.,Ltd. (KOSDAQ:251120)
Aug 06Revenue & Expenses Breakdown
How BIO-FD&CLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 25 | 18,816 | 7,083 | 4,482 | 1,619 |
| 30 Jun 25 | 17,342 | 6,211 | 4,372 | 1,615 |
| 31 Mar 25 | 16,590 | 5,037 | 4,091 | 1,862 |
| 31 Dec 24 | 16,066 | 4,501 | 4,305 | 1,699 |
| 30 Sep 24 | 16,067 | 5,099 | 3,943 | 2,026 |
| 30 Jun 24 | 16,397 | 5,174 | 4,122 | 1,871 |
| 31 Mar 24 | 16,059 | 5,808 | 4,550 | 1,187 |
| 31 Dec 23 | 15,592 | 5,585 | 4,323 | 1,429 |
| 30 Sep 23 | 14,947 | 4,725 | 4,587 | 1,088 |
| 30 Jun 23 | 13,988 | 4,337 | 4,128 | 1,326 |
| 31 Mar 23 | 14,832 | 5,120 | 4,258 | 1,467 |
| 31 Dec 22 | 15,855 | 4,335 | 4,538 | 1,449 |
| 30 Sep 22 | 16,368 | 3,874 | 4,331 | 1,256 |
| 30 Jun 22 | 15,881 | 3,691 | 4,400 | 990 |
| 31 Mar 22 | 14,092 | 2,517 | 3,534 | 1,285 |
| 31 Dec 21 | 11,972 | 2,908 | 2,959 | 816 |
| 30 Sep 21 | 9,467 | 2,511 | 2,506 | 818 |
| 31 Dec 20 | 8,640 | 2,461 | 1,799 | 739 |
| 31 Dec 19 | 8,476 | 2,562 | 1,623 | 937 |
| 31 Dec 18 | 5,998 | 394 | 1,309 | 1,255 |
| 31 Dec 16 | 4,610 | 695 | 1,299 | 927 |
| 31 Dec 15 | 3,977 | 891 | 879 | 603 |
Quality Earnings: A251120 has high quality earnings.
Growing Profit Margin: A251120's current net profit margins (37.6%) are higher than last year (31.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A251120's earnings have grown by 19% per year over the past 5 years.
Accelerating Growth: A251120's earnings growth over the past year (38.9%) exceeds its 5-year average (19% per year).
Earnings vs Industry: A251120 earnings growth over the past year (38.9%) did not outperform the Biotechs industry 39.9%.
Return on Equity
High ROE: A251120's Return on Equity (10.3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/18 17:59 |
| End of Day Share Price | 2025/11/18 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BIO-FD&C Co.,Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eui-Seob Shim | NH Investment & Securities Co., Ltd. |